Short CommunicationMODULATION OF CELL SURFACE MARKERS ON NK-LIKE T LYMPHOCYTES BY USING IL-2, IL-7 OR IL-12 IN VITRO STIMULATION
References (14)
- et al.
Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+killer cells
Blood
(1995) - et al.
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells
Cell Immunol
(1996) - et al.
Comparative studies of CD3−and CD3+CD56+cells: Examination of morphology, functions, T cell receptor rearrangement and pore-forming protein expression
Cell Immunol
(1991) - et al.
Expansion of Philadelphia chromosome-negative CD3+CD56+cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice
Blood
(1998) - et al.
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
J Exp Med
(1991) - et al.
Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine-induced killer cells
Experimental Hematology
(1993) - et al.
Activated T cells and cytokine-induced CD3+CD56+killer cells
Ann Hematol
(1997)
Cited by (37)
IL12 integrated into the CAR exodomain converts CD8<sup>+</sup> T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors
2022, Molecular TherapyCitation Excerpt :Taken together, gene expression profiling implied a novel phenotype of NK-like T cells induced upon signaling through the IL12-CAR. The CD8+CD56+CD62Lhigh phenotype of IL12-CAR T cells resembled, although was not identical to, CIK cells,20,21 the recently described poly-functional NK cells,22 and anti-microbial cytotoxic T cells.23 CD94/NKG2A was highly upregulated in IL12-CAR T cells compared with conventional CAR T cells (Figure 4A).
Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway
2016, Human ImmunologyCitation Excerpt :High variability in the range of CIK proliferation, from few to more than 1000 fold expansion, has been reported, suggesting that some patient/donor might be classified as “poor CIK expander” [13–15]. Considering that the recruitment of a sufficient number of immune cells capable to be specifically effective against tumor target cells is a crucial issue for adoptive immunotherapy, alternative strategies, based on additional soluble factors such as IL-1, IL-7, IL-12 or on allogeneic stimulation by irradiated PBMC, have been investigated to ameliorate both the number and the anti-tumor cytotoxic potential of CIK [16–18]. Moreover, immunotherapy approaches combining different immune effector cells have also been explored and, the association of DC, CTL and CIK have displayed encouraging results in the treatment of various malignant tumors [19].
A role for interleukin-12/23 in the maturation of human natural killer and CD56<sup>+</sup> T cells in vivo
2008, BloodCitation Excerpt :CD56+ T cells thus have attributes of effector memory CD8 T cells, although the precise steps of differentiation of CD56+ T cells from naive CD8 T cells are still unknown. In vitro data have argued for a role for IL-12 in their development and/or expansion,52-55 but one report disputed the in vivo relevance of these findings for the pool of hepatic CD56+ T cells.55 We also previously showed that most CD56+ T cells constitutively express IL-12Rβ1.56
Adoptive cell therapies in thoracic malignancies
2022, Cancer Immunology, ImmunotherapyEffects of interleukin-2 concentration and administration method on proliferation and function of cytokine-induced killer cells
2021, Translational Cancer ResearchCD28null and regulatory T cells are substantially disrupted in patients with end-stage renal disease due to diabetes mellitus
2021, International Journal of Molecular Sciences
- f1
Correspondence to: Ingo G. H. Schmidt-Wolf, M.D., Medizinische Universitätsklinik und Poliklinik I, Sigmund-Freud-Str. 25, 53105 Bonn, Germany